Add to my selection

POLIVY

Medicine - Posted on Jan 09 2023

Active substance (DCI)

polatuzumab vedotin

history (2)

12/7/22

POLIVY (polatuzumab védotine) - Lymphome non hodgkinien (LDGCB)

Key points Disapproval of reimbursement of POLIVY (polatuzumab vedotin), in association with rituximab, cyclophosphamide, do...

CAV :
54321

icône flèche
6/10/20

POLIVY

First assessment. Unfavourable opinion for reimbursement in combination with bendamustine and rituximab in the treatment of ...

CAV :
54321

icône flèche

Technical information

ATC code

L01XC37

Manufacturer

ROCHE

Presentation

POLIVY 140 mg, poudre pour solution à diluer pour perfusion
1 flacon en verre de 20 ml (CIP : 34009 550 700 3 0)

POLIVY 30 mg, poudre pour solution à diluer pour perfusion
1 flacon en verre de 6 ml (CIP : 34009 550 799 6 5)

All our publications

Cancers - miscellaneous

Hematologic cancers